Shuichan Xu

This inventor holds 26 USPTO granted patents and 15 published patent applications, plus 6 CIPO patents and 16 EPO patents, primarily in Cancer Treatment. Top assignees: Signal Pharmaceuticals, Inc., Celgene Corporation. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuichan Xu. Retrieved from https://idiyas.com/inventor/shuichan-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 15)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 16 (Patent Applications = 26)

Average Co-Inventor Count = 5.9

ph-index = 7

Forward Citations = 195(Granted Patents)

Company Filing History:

21 out of 169

Signal Pharmaceuticals, Inc.

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Cancer Treatment

TOR Kinase Inhibitors

Aminopurine Compounds

Chimeric Antigen Receptors

Pyrrolopyrimidine Compounds

Biomarkers

Combination Therapy

Dihydropyrazino-pyrazines

Phosphorylation Inhibition

Predictive Biomarkers

3-Aminophenyl Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2025-09-02),

2. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2024-01-16),

3. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2023-02-28),

4. 11331380 - Cereblon-based heterodimerizable chimeric antigen receptors (2022-05-17),

5. 11325889 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2022-05-10),

6. 11166950 - Treatment of cancer with TOR kinase inhibitors (2021-11-09),

7. 11149007 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2021-10-19),

8. 10940152 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2021-03-09),

9. 10646493 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-05-12),

10. 10576085 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-03-03),

11. 10004735 - Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines (2018-06-26),

12. 9980963 - Treatment of cancer with dihydropyrazino-pyrazines (2018-05-29),

13. 9937170 - Treatment of cancer with TOR kinase inhibitors (2018-04-10),

14. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),

15. 9737541 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2017-08-22),

Title: **Shuichan Xu: Innovator in Pharmaceutical Compounds**

Introduction

Shuichan Xu, based in San Diego, California, is a prominent inventor with a remarkable portfolio comprising 25 patents. His work primarily focuses on pharmaceutical compounds, contributing significantly to the field of medicinal chemistry and treatment methodologies.

Latest Patents

Shuichan Xu's recent patents showcase his innovative approaches to compound development. His latest inventions include:

1. **Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith** - This patent presents novel piperidine dione compounds with specific structural attributes for therapeutic uses.

2. **Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith** - This invention describes aminopurine compounds featuring defined structures, aimed at enhancing treatment options in various medical fields.

Career Highlights

Throughout his career, Shuichan Xu has been associated with leading pharmaceutical companies. Notable among them are Signal Pharmaceuticals, Inc. and Celgene Corporation, where he has played a critical role in advancing drug development processes.

Collaborations

Shuichan Xu has collaborated with talented individuals such as Tam Minh Tran and Heather K Raymon, contributing to a rich exchange of ideas and innovations in the field of pharmaceutical research.

Conclusion

Shuichan Xu's extensive patent portfolio and innovative contributions reflect his dedication to advancing healthcare solutions. His work continues to inspire and pave the way for future inventions in the pharmaceutical industry.

Profile summary based on public USPTO records.